$A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)$

A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Abstract Purpose To assess the safety and efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Experimental design Relapsed or refractory DLBCL patients originally received the oral spleen tyrosine kinase inhibitor, fostamatinib in a two-arm, random...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2016-02, Vol.54, p.11-17
Hauptverfasser:	Flinn, Ian W, Bartlett, Nancy L, Blum, Kristie A, Ardeshna, Kirit M, LaCasce, Ann S, Flowers, Christopher R, Shustov, Andrei R, Thress, Kenneth S, Mitchell, Patrick, Zheng, Fred, Skolnik, Jeffrey M, Friedberg, Jonathan W
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Aged Aged, 80 and over Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use B-cell receptor Clinical trial Disease Progression DLBCL Drug Administration Schedule Drug Resistance, Neoplasm Female Hematology, Oncology and Palliative Medicine Humans Intracellular Signaling Peptides and Proteins - antagonists & inhibitors Intracellular Signaling Peptides and Proteins - metabolism Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - enzymology Lymphoma, Large B-Cell, Diffuse - pathology Male Middle Aged Oxazines - administration & dosage Oxazines - adverse effects Oxazines - therapeutic use Phase II Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Protein-Tyrosine Kinases - antagonists & inhibitors Protein-Tyrosine Kinases - metabolism Pyridines - administration & dosage Pyridines - adverse effects Pyridines - therapeutic use Recurrence Syk inhibitor Syk Kinase Time Factors Treatment Outcome United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!